rs63750466

Variant names:

• chr2-47403195-G-A
• rs63750466
• NM_000251.3:c.4G>A

Your query was ambiguous. Multiple possible variants found:

• chr2-47403195-G-A
• chr2-47403195-G-C
• chr2-47403195-G-T

Variant summary

Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP6_Very_Strong

The NM_000251.3(MSH2):​c.4G>A​(p.Ala2Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00016 in 1,595,188 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely benign (★★★). Synonymous variant affecting the same amino acid position (i.e. A2A) has been classified as Likely benign.

• Frequency:
  • Genomes: 𝑓 0.000072 (0 hom., cov: 33)
  • Exomes 𝑓: 0.00017 (0 hom.)
• Consequence: MSH2 NM_000251.3 missense
• Clinical Significance: Likely benign reviewed by expert panel U:9 B:12
• Conservation: PhyloP100: 8.80

Genes affected

MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]

ACMG classification

Verdict is Benign. Variant got -8 ACMG points.

• BP6: Variant 2-47403195-G-A is Benign according to our data. Variant chr2-47403195-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 41650.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr2-47403195-G-A is described in Lovd as [Likely_benign]. Variant chr2-47403195-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
MSH2	NM_000251.3	c.4G>A	p.Ala2Thr	missense_variant	Exon 1 of 16	ENST00000233146.7	NP_000242.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
MSH2	ENST00000233146.7	c.4G>A	p.Ala2Thr	missense_variant	Exon 1 of 16	1	NM_000251.3	ENSP00000233146.2

Frequencies

GnomAD3 genomes AF: 0.0000722 AC: 11 AN: 152258 Hom.: 0 Cov.: 33

Gnomad AFR AF: 0.00

Gnomad AMI AF: 0.00

Gnomad AMR AF: 0.00

Gnomad ASJ AF: 0.00

Gnomad EAS AF: 0.00

Gnomad SAS AF: 0.00

Gnomad FIN AF: 0.000188

Gnomad MID AF: 0.00

Gnomad NFE AF: 0.000132

Gnomad OTH AF: 0.00

GnomAD3 exomes AF: 0.000152 AC: 33 AN: 216606 Hom.: 0 AF XY: 0.000119 AC XY: 14 AN XY: 117838

Gnomad AFR exome AF: 0.00

Gnomad AMR exome AF: 0.00

Gnomad ASJ exome AF: 0.00

Gnomad EAS exome AF: 0.00

Gnomad SAS exome AF: 0.00

Gnomad FIN exome AF: 0.000391

Gnomad NFE exome AF: 0.000259

Gnomad OTH exome AF: 0.000185

GnomAD4 exome AF: 0.000170 AC: 245 AN: 1442930 Hom.: 0 Cov.: 31 AF XY: 0.000173 AC XY: 124 AN XY: 716142

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.000357

Gnomad4 NFE exome AF: 0.000197

Gnomad4 OTH exome AF: 0.000151

GnomAD4 genome AF: 0.0000722 AC: 11 AN: 152258 Hom.: 0 Cov.: 33 AF XY: 0.0000807 AC XY: 6 AN XY: 74390

Gnomad4 AFR AF: 0.00

Gnomad4 AMR AF: 0.00

Gnomad4 ASJ AF: 0.00

Gnomad4 EAS AF: 0.00

Gnomad4 SAS AF: 0.00

Gnomad4 FIN AF: 0.000188

Gnomad4 NFE AF: 0.000132

Gnomad4 OTH AF: 0.00

Alfa AF: 0.000193 Hom.: 0

Bravo AF: 0.0000982

ExAC AF: 0.000141 AC: 17

ClinVar

Significance: Likely benign

Submissions summary: Uncertain:9 Benign:12

Revision: reviewed by expert panel

Submissions by phenotype

not provided Uncertain:3 Benign:2

Feb 06, 2018

ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The MSH2 c.4G>A; p.Ala2Thr variant (rs63750466) is reported in the literature in multiple individuals with Lynch syndrome (Kurzawski 2006, Mangold 2005a, Mangold 2005b, Nagasaka 2010, Pagenstecher 2006, Parc 2003). However, it has been reported to co-occur with a pathogenic MSH2 nonsense variant (Mangold 2005a) and a 3'EPCAM deletion where MSH2 promoter methylation was seen (Nagasaka 2010). This variant is also reported to co-segregate with disease in a large Lynch syndrome family where loss of the MSH2 protein was seen in four individual's tumors; however, RNA analysis showed normal expression, suggesting this variant may be a marker in this family but the functional consequences are uncertain (Pagenstecher 2006). This variant is considered uncertain by an expert review panel in ClinVar (Variation ID: 41650), and is found in the general population with an overall allele frequency of 0.01% (34/241756 alleles) in the Genome Aggregation Database. This variant occurs in a conserved nucleotide of the Kozak consensus sequence, but computational algorithms do not agree as to the effect this variant may have on the protein (SIFT: Tolerated, PolyPhen2: Probably Damaging). Based on available information, the clinical significance of p.Ala2Thr is uncertain at this time. REFERENCES Kurzawski G et al. Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clin Genet. 2006 Jan;69(1):40-7. Mangold E et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer. 2005a Sep 20;116(5):692-702. Mangold E et al. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol. 2005b Dec;207(4):385-95. Nagasaka T et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res. 2010 Apr 15;70(8):3098-108. Pagenstecher C et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet. 2006 Mar;119(1-2):9-22. Parc Y et al. Cancer risk in 348 French MSH2 or MLH1 gene carriers. J Med Genet. 2003 Mar;40(3):208-13. -

Aug 09, 2021

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Nov 06, 2018

GeneDx

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Jul 13, 2012

Biesecker Lab/Clinical Genomics Section, National Institutes of Health

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: research

- -

Nov 03, 2021

Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Uncertain:1 Benign:3

Jan 01, 2022

Color Diagnostics, LLC DBA Color Health

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Apr 09, 2021

Sema4, Sema4

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: curation

- -

Sep 24, 2018

Ambry Genetics

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Jun 11, 2024

Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

not specified Uncertain:1 Benign:2

May 03, 2019

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Variant summary: MSH2 c.4G>A (p.Ala2Thr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. 5/5 computational tools predict no significant impact on normal splicing. This was confirmed by RT-PCR results (Pagenstecher_2006). The variant allele was found at a frequency of 0.00016 in 217422 control chromosomes (gnomAD and publication data). This frequency is not significantly higher than expected for a pathogenic variant in MSH2 causing Lynch Syndrome (0.00016 vs 0.00057), allowing no conclusion about variant significance. The variant, c.4G>A, has been reported in the literature in individuals affected with Lynch Syndrome, uveal malignant melanoma or autosomal dominant cancer predisposition syndromes (Mangold_2005, Kurzawski_2006, Schrader_2016, Bonadona_2011, Hajkova_2018, Zhang_2015). One publication reported one family where it showed segregation of this variant with Lynch syndrome (Mangold_2005). However, in many reports, not all MMR genes were tested or MLPA applied. Consequently, these reports do not provide unequivocal conclusions about association of the variant with Lynch Syndrome. Furthermore, in some of these families co-occurrences with other pathogenic variants have been reported (MSH2 c.1835C>G, p.Ser612X (Mangold_2005); EPCAM deletion associated with MSH2 promoter methylation (Nagasaka_2010); MSH2 c.1delA (UMD); RAD51C c.97C>T, p.Gln33X (Internal database)), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories and one expert panel (InSiGHT) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Likely benign (n=4 to include the expert panel), VUS (n=3)). Based on the evidence outlined above, the variant was classified as likely benign. -

Mar 04, 2025

Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

-

Mayo Clinic Laboratories, Mayo Clinic

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: research

- -

Lynch syndrome 1 Uncertain:1 Benign:2

Jul 05, 2016

Counsyl

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Dec 02, 2024

Myriad Genetics, Inc.

Significance: Benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant is considered benign. This variant has been observed in trans with a known pathogenic variant in one or more individuals lacking clinical features consistent with gene-specific recessive disease. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 27363726]. -

Jun 13, 2018

International Society for Gastrointestinal Hereditary Tumours (InSiGHT)

Significance: Likely benign

Review Status: reviewed by expert panel

Collection Method: curation

Multifactorial likelihood analysis posterior probability < 0.05 (0.006) -

Breast and/or ovarian cancer Uncertain:1

Oct 08, 2021

CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Malignant tumor of breast Uncertain:1

-

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

The MSH2 p.Ala2Thr variant was identified in 15 of 38724 proband chromosomes (frequency: 0.0004) from individuals or families with lynch syndrome or colorectal cancer (Bonadona 2011, Dymerska 2010, Johnston 2012, Kurzawski 2006, Mangold 2005, Nagasaka 2010, Parc 2003). The variant was identified in dbSNP (ID: rs63750466) as “With Uncertain significance allele”, ClinVar (as uncertain significance, reviewed by an expert panel including 6x as uncertain significance and 2x as likely benign), Clinvitae (5x), UMD-LSDB (30x as neutral), Mismatch Repair Genes Variant Database, and in the Insight Hereditary Tumors database (19x). In UMD the variant was identified with a co-occurring pathogenic MSH2 variant (c.1delA, p.Met1?), increasing the likelihood that the p.Ala2Thr variant does not have clinical significance. The variant was not identified in the COGR, Cosmic, MutDB, or Zhejiang University databases. The variant was identified in control databases in 34 of 241756 chromosomes at a frequency of 0.0001 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: “Other” in 1 of 5740 chromosomes (freq: 0.0002), European in 25 of 109176 chromosomes (freq: 0.0002), and Finnish in 8 of 21430 chromosomes (freq: 0.0004); it was not observed in the African, Latino, Ashkenazi Jewish, East Asian, or South Asian populations. The p.Ala2 residue is conserved across mammals and other organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In one study, Immunohistochemical analysis of this variant in tumors from relatives (mother and son - both of whom were carriers of the variant) revealed a loss of MSH2 protein expression; this finding supported a pathogenic role for the MSH2, c.4G>A, p.Ala2Thr variant (Mangold 2005). In another publication this variant is reported to segregate with the disease in several family members (at least 10 meioses) and showed loss of MSH2 expression in tumors of four affected family members. This variant is clearly linked to the disease in this specific family (Pagenstecher 2006). However, there is conflicting evidence in the literature; this variant was identified in an individual as co-occurring with pathogenic variant in MSH2 (c.1835C>G, p.S612X) (Lucci-Cordisco 2006, Mangold 2005). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. -

Breast carcinoma Uncertain:1

Jan 01, 2019

Institute of Human Genetics, University of Leipzig Medical Center

Significance: Uncertain significance

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

MSH2-related disorder Benign:1

Jan 28, 2021

PreventionGenetics, part of Exact Sciences

Significance: Likely benign

Review Status: no assertion criteria provided

Collection Method: clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Lynch syndrome Benign:1

Feb 01, 2018

University of Washington Department of Laboratory Medicine, University of Washington

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

MSH2 p.A2T has been reported to co-occur with a MSH2 nonsense variant and a 3' EPCAM deletion where MSH2 promoter methylation was identified (Mangold 2005, Nagasaka 2010). Functional RNA studies performed on peripheral blood found normal RNA levels in patients that carry p.A2T (Pagenstecher 2006). MSH2 p.A2T was observed at an allele frequency of 0.0724% (14/19320 alleles) in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016), and it was observed in 1/208 individuals with atherosclerosis, with no specific information about cancer history (Johnston 2012). -

Hereditary nonpolyposis colorectal neoplasms Benign:1

Feb 04, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Likely benign

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Pathogenic	0.75
BayesDel_addAF	Pathogenic	0.26	D
BayesDel_noAF	Pathogenic	0.43
CADD	Uncertain	25
DANN	Pathogenic	1.0
DEOGEN2	Benign	0.41	T;.;.
Eigen	Uncertain	0.68
Eigen_PC	Pathogenic	0.71
FATHMM_MKL	Pathogenic	0.99	D
LIST_S2	Uncertain	0.89	D;D;D
M_CAP	Pathogenic	0.53	D
MetaRNN	Uncertain	0.71	D;D;D
MetaSVM	Uncertain	0.72	D
MutationAssessor	Benign	1.8	L;.;.
PrimateAI	Uncertain	0.76	T
PROVEAN	Benign	-1.6	N;.;N
REVEL	Pathogenic	0.84
Sift	Uncertain	0.0030	D;.;D
Sift4G	Uncertain	0.011	D;.;T
Polyphen		1.0	D;.;D
Vest4		0.72
MVP		0.97
MPC		0.032
ClinPred		0.49	T
GERP RS		5.4
RBP_binding_hub_radar		0.92
RBP_regulation_power_radar		2.7
Varity_R		0.78
gMVP		0.63

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs63750466; hg19: chr2-47630334;